Anno II | Numero 9 | Gennaio 2017
Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio
Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
Notizie dalla ricerca

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor …
Continua a leggere
Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors
Abscopal effect is a rare phenomenon characterized by tumor regression of untreated metastatic lesions after a local therapy (eg, radiotherapy). We studied the probability of abscopal effect with radiotherapy associated with anti-programmed death cell 1 (PD1) therapy after progression on anti-PD1. This study is a retrospective analysis of patients treated with nivolumab or pembrolizumab for melanoma, non-small cell lung cancer (NSCLC) and renal cancer at Antônio Ermírio de Moraes Oncology Center …
Continua a leggere
Tim-3 expression on tumor-infiltrating PD-1+CD8+T cells correlates with poor clinical outcome in renal cell carcinoma
Inhibitory receptors expressed by T cells mediate tolerance to tumor antigens with coexpression of these receptors exacerbating this dysfunctional state. Using the VectraR automated multiparametric immunofluorescence technique, we quantified intratumoral CD8+T cells coexpressing the inhibitory receptors PD-1 and Tim-3 from patients with renal cell carcinoma (RCC). A second validation cohort measured the same parameters by cytometry. The percentage of tumor-infiltrating CD8+T cells …
Continua a leggere
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
Renal cell carcinoma (RCC) is a complex disease characterized by mutations in several genes. Loss of function of the von Hippel-Lindau (VHL) tumour suppressor gene is a very common finding in RCC and leads to up-regulation of hypoxia-inducible factor (HIF)-responsive genes accountable for angiogenesis and cell growth, such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). Binding of these proteins to their cognate tyrosine kinase receptors on endothelial …
Continua a leggere
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Immuno-oncology (I-O) therapies target the host immune system, providing the potential to choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually occurs early in clinical development and is typically based on tumor response, which may not fully represent the potential for improved overall survival. Here, we describe an integrated approach which incorporates clinical safety and efficacy data with data obtained from analyses of dose-/exposure-response …
Continua a leggere
Appuntamenti AIOM

Aggiornamenti in Oncologia: Iponatriemia
Verona, 26 – 27 gennaio 2017
Innovative Therapy, Monoclonal Antibodies and Beyond – 7th Edition
Milano, 27 gennaio 2017
Metodologia della Ricerca Clinica
Corso teorico pratico: “Come si scrive un protocollo di ricerca clinica”
Negrar, 31 gennaio – 1 febbraio 2017
Revisioni Sistematiche e Meta-Analisi
Negrar, 10 – 11 febbraio 2017
Iscrizioni entro il 3 febbraio
Corso Base di Formazione in Psiconcologia per Psicologi e Medici
XX Edizione
Milano, 20 – 23 febbraio 2017 (I modulo)
Milano, 27 – 30 marzo 2017 (II modulo)
AIOM Post ASCO GU Review
UPDATES and NEWS from the Genitourinary Cancers Symposium in Orlando, FL, USA
Milano, 3 marzo 2017
Studi Clinici: Metodologia
A good foundation
Negrar (VR), 8 – 9 marzo 2017
Studi Clinici: Criticità Interpretative
Confidence, directness, relevance
Negrar (VR), 24 – 25 marzo 2017
Immunoterapia nei Tumori del Polmone e dell’Urotelio
A che punto siamo?
Roma, 27 – 28 marzo 2017
Conferenza Nazionale CIPOMO
La gestione del rischio in oncologia tra sicurezza e qualità
Ascoli Piceno, 31 marzo – 1 aprile 2017

Questi e altri appuntamenti si possono consultare sul sito AIOM

Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Per contattare la redazione e commentare le notizie clicca qui: redazione
Per consultare i numeri arretrati della newsletter clicca qui: archivio
Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI

Questo progetto è stato realizzato con il contributo di